In this heavy biotech action Hospira sought to revoke three of Genentech’s patents relating to the blockbuster Herceptin monoclonal antibody product, as well as seeking a declaration of non-infringement. The patents related to issues of product purity and dosage regimens, with technical evidence being given by six experts, and particularly focussed on issues of novelty, obviousness and priority. Richard Meade QC acted for the claimant, Michael Tappin QC and Mark Chacksfield acted for the defendant.
+44(0)20 7405 4321
clerks@8newsquare.co.uk